Results

1–10 of 120 results for clinical trials

Characterization of Eyes With Geographic Atrophy That Developed Macular Neovascularization in the GATHER Clinical Trials
Dilraj S Grewal, MD, FASRS
Annual Meeting Talks
2024
Baseline Ellipsoid Zone Integrity Features as Predictors of Geographic Atrophy Growth Rate in the Phase 3 GATHER Clinical Trials
Katherine E Talcott, MD
Annual Meeting Talks
2024
1-Year Results of a Phase 2 Pharmacodynamic Study: Subretinal Delivery of Investigational Gene Therapy ABBV-RGX-314 for Neovascular AMD
Robert L. Avery, MD
Updates from the Field
2025
LIGHTSITE IIIB: A Prospective, Multi-Center Extension Study to Assess the Long-Term Safety and Efficacy of Photobiomodulation in Dry Age-Related Macular Degeneration
David S. Boyer, MD
Updates from the Field
2025
Ixoberogene Soroparvovec (Ixo-vec) IVT Gene Therapy for Neovascular AMD: First Time 26-Week Interim Analysis Results from the Phase 2 LUNA Study
Charles C Wykoff, MD, PhD, FASRS
Updates from the Field
2024
Masked Safety Data from ZETA-1, an Ongoing 24-Week Phase 2 Clinical Trial of APX3330, an Oral Therapeutic Being Developed for the Treatment of Diabetic Retinopathy
Michael J Allingham, MD, PhD
Annual Meeting Talks
2022
Interim Subretinal Gene Therapy Safety Results in Two Phase 1/2 Open-label, Dose-Escalation Clinical Trials to Treat Achromatopsia
Lejla Vajzovic, MD, FASRS
Annual Meeting Talks
2022
Outcomes of the HORNBILL Study: A Phase I/IIa Trial Investigating BI 764524 in Patients With Diabetic Macular Ischemia
Quan Dong Nguyen, MD, MSc, FARVO, FASRS
Updates from the Field
2024
Detailed Baseline Demographics and Disease Characteristics of Patients With Geographic Atrophy Enrolled in the Phase 3 OAKS and DERBY Clinical Trials
On Demand Cases, Courses, and Papers
2022
GATHER2 Phase 3 Efficacy Results and GATHER2 Phase 3 Safety Results
Jeffrey S. Heier, MD
Arshad M. Khanani, MD, MA, FASRS
Updates from the Field
2022